Strides announces successful completion of UK MHRA inspection at Puducherry facility

Strides Pharma Science Limited (Strides) today announced the successful completion of the inspection carried out by the UK Medicines and Healthcare products Regulatory Agency (UK MHRA) at its Puducherry facility between 15-18 October 2019. The Company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection. The Puducherry facility caters to the U.S., Other Regulated Markets and Institutional businesses and has capabilities to produce finished dosage formulation products across multiple dosage formats.

Commenting on the development, Dr. R. Ananthanarayanan, Managing Director & CEO, remarked "We are pleased with the positive outcome of the inspection by the UK MHRA at our Puducherry facility. The inspection was conducted a few months after the USFDA inspection that resulted in the Warning Letter. We stay focused on getting the facility reclassified with the USFDA. We are committed to upholding the highest levels of quality compliance and integrity across all our manufacturing sites".

Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.568.85 as compared to the previous close of Rs. 554.85. The total number of shares traded during the day was 120996 in over 2763 trades.

The stock hit an intraday high of Rs. 583.2 and intraday low of 556.85. The net turnover during the day was Rs. 69255034.

Source : Equity Bulls

Keywords